【Intro】Medigen Vaccine Biologics Corp.

撰文新聞中心
日期2021-07-15
Medigen Vaccine Biologics Corp.

Company Introduction

高端疫苗為開發與量產疫苗及生物製劑的生技新藥公司,運用細胞培養技術,並透過國際合作聯盟,發展病毒性疫苗及生物相似藥。本公司立足台灣,將優先以台灣需求產品作為開發標的,提供創新的醫藥產品,守護全民的健康安全。同時,期望能成為亞太區的研發和量產中心,進而放眼世界,保障全體人類免於眾多疾病的威脅。

Medigen Vaccine Biologics Corp. (MVC) is a biopharmaceutical company using cell-based technologies to develop novel vaccines and biosimilars. With a goal of national self-sufficiency, MVC also aims to provide vaccines and biopharmaceuticals to meet regional needs and with a desire to help globally against the threats of infectious diseases. MVC's pipeline includes COVID-19 vaccine, enterovirus EV71 vaccine, dengue vaccine, influenza quadrivalent vaccine which all have entered late clinical stage. MVC's large-scale production facility is state of the art and adherent to international PIC/s GMP requirements.

Brief description of main products or services 

MVC is developing a portfolio of COVID-19 vaccine candidates in order to assist with local, regional and global recovery efforts. The leading candidate in MVC’s portfolio is an intramuscular vaccine based on the prefusion stabilized spike protein, S-2P, licensed from U.S. NIH. Preclinical and clinical results indicate a strong COVID-19 vaccine candidate likely to be effective in preventing severe infection and an ideal candidate to assist in the global fight against COVID-19 due to favorable cold chain requirements.

MVC’s Enterovirus 71 (EV71) vaccine has completed its Phase III clinical trial in Vietnam and Taiwan in Q2 2021 and has shown to induce sufficient neutralizing antibodies in participants. Once approved by regulatory authorities it will be the world’s first EV71 vaccine approved from 2 months old to 6 years of age. Clinical data also shows cross-reaction to B4, B5, C4 and C5 subtypes.

Recently, MVC completed Phase II clinical study in the elderly for a Dengue vaccine candidate and have been developing a lyophilized version of the liquid formulation licensed from U.S. MVC has also partnered with GC Pharma from Korea for the importation of Seasonal Influenza QIV. MVC will continue to develop new vaccines locally and with global partners to assist with new emerging diseases.

線上報名 查看更多